Press release

Press release

04 May 2026 – OneSource Supports Second Generic Semaglutide Approval in Canada
29 Apr 2026 – OneSource’s Partner Dr. Reddy’s Laboratories receives Health Canada Approval for Generic Semaglutide Injection
21 Apr 2026 – Orbicular’s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner
11 Feb 2026 – OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic® in Saudi Arabia
23 Jan 2026 – OneSource Q3FY26 Results: Transitional quarter – Revenue deferred pending customer approvals for Semaglutide in Canada
12 Nov 2025 – OneSource reports Q2FY26 performance with revenue growth of 12% and margin expansion of 506 bps YoY
04 Aug 2025 – OneSource reports Q1FY26 performance in line with our expectations
11 Jun 2025 – OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
10 Jun 2025 – OneSource’s flagship drug-device combinations facility in Bangalore maintains its USFDA compliance status
05 May 2025 – OneSource Reports Strong Q4 and FY25 Results – Q4FY25 Revenues of ₹4,260 million with an EBTDA of ₹1,825 million, demonstrating EBITDA margin of 43%
10 Apr 2025 – OneSource Secures approval from Brazil for its flagship facility
28 Feb 2025 – OneSource strengthens its Board by appointing three new Independent Directors
29 Jan 2025 – OneSource announces strong financial results in its first quarter post listing; Q3FY25 revenues at ₹3,926 million with an EBITDA of ₹1,432 million, demonstrating a 36.5% EBITDA margin
28 Jan 2025 – OneSource receives EIR with ‘Voluntary Action Indicated’ classification from USFDA for its BLD Facility
16 Oct 2024 – Press Release w.r.t Equity Commitments received by the Company from marquee Investors